Literature DB >> 9586229

Characterization of polar urinary metabolites by ionspray tandem mass spectrometry following dansylation.

D K Dalvie1, J P O'Donnell.   

Abstract

The present report illustrates the application of dansyl chloride coupled with ion spray tandem mass spectrometry (IS-MS/MS) in identifying polar urinary metabolites. In the course of the metabolism studies of a drug that is currently in development, the urine from rats and dogs was collected following oral administration of radiolabelled compound. Urinary metabolic profiles of the rat and dog indicated the presence of four major peaks and one major peak, respectively, in the radiochromatogram. Since all attempts to identify the peaks by conventional MS/MS techniques failed, the metabolites were isolated by fraction collection and dansylated. Derivatization of the metabolites resulted in the formation of more hydrophobic, readily ionizable species which were more sensitive in IS-MS/MS analysis than the underivatized metabolites. Examination of the molecular ions and the product ion mass spectra of these derivatives revealed the structures of all the urinary metabolites. The metabolites in the rat and the dog were 4-hydroxyphenylpiperazine glucuronide (M1), 1,4-dihydroxyphenyl glucuronide (M2), 1,4-dihydroxyphenyl sulfate (M3) and phenylpiperazine (M4). Thus, derivatization with dansyl chloride in conjunction with tandem mass spectrometry is a useful tool in identifying polar urinary metabolites.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9586229     DOI: 10.1002/(SICI)1097-0231(19980430)12:8<419::AID-RCM176>3.0.CO;2-S

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  2 in total

1.  Dansylation of unactivated alcohols for improved mass spectral sensitivity and application to analysis of cytochrome P450 oxidation products in tissue extracts.

Authors:  Zhongmei Tang; F Peter Guengerich
Journal:  Anal Chem       Date:  2010-09-15       Impact factor: 6.986

2.  Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI.

Authors:  Paul Sirajuddin; Sudeep Das; Lymor Ringer; Olga C Rodriguez; Angiela Sivakumar; Yi-Chien Lee; Aykut Üren; Stanley T Fricke; Brian Rood; Alpay Ozcan; Sean S Wang; Sana Karam; Venkata Yenugonda; Patricia Salinas; Emanuel Petricoin; Michael Pishvaian; Michael P Lisanti; Yue Wang; Richard Schlegel; Bahram Moasser; Chris Albanese
Journal:  Cell Cycle       Date:  2012-09-14       Impact factor: 4.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.